The job of an investor is to buy top-notch companies in essential economic sectors at reasonable valuations and hold them over the long term.
Because everyone will need access to healthcare services in their life, healthcare is an especially important sector of the economy. In that spirit, here are two healthcare giants with promising fundamentals and valuations that could lead to significant capital appreciation both in and well past 2023.
Sanofi (NASDAQ: SNY) is likely best known for its smash-hit immunology drug co-owned with Regeneron (NASDAQ: REGN) called Dupixent. The company's share of sales from the drug through the first three quarters of 2022 topped $6 billion, which was up 44.5% over the year-ago period. Considering that Dupixent was recently approved for more indications like eosinophilic esophagitis , sales should continue to move higher.
For further details see:
Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023